MWNA
KROS icon

Marshall Wace North America’s Keros Therapeutics KROS Stock Holding History

Marshall Wace North America’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-108,059
Closed -$6.65M – 1624
2021
Q1 		$6.65M Buy
+108,059
New +$6.85M 0.03% 492

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Marshall Wace North America's KROS Position: Q2 2021 in Review

Marshall Wace North America sold out of Keros Therapeutics (KROS) in Q2 2021, closing a stake of 108,059 shares — an estimated $6.65M sold.

Marshall Wace North America first reported a position in KROS in Q1 2021 and held it in 1 quarter. The position peaked at $6.65M in Q1 2021. 80 funds tracked by Wall St. Rank hold KROS as of Q2 2021.

  • Marshall Wace North America reported no remaining Keros Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 108,059 Keros Therapeutics shares in Q2 2021, an estimated $6.65M.
  • Marshall Wace North America first reported a position in Keros Therapeutics in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Keros Therapeutics position peaked at $6.65M in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.